首页> 外文期刊>Biopreservation and biobanking >Cryopreservation: An Optimizing Factor for Therapeutic Potential of Fetoplacental Complex Products
【24h】

Cryopreservation: An Optimizing Factor for Therapeutic Potential of Fetoplacental Complex Products

机译:冷冻保存:胎盘复合物治疗潜力的优化因素

获取原文
获取原文并翻译 | 示例
           

摘要

The therapeutic potential of cryopreserved fetoplacental complex cells (FPCP) has been explored for the treat-ment of autoimmune diseases, including autoimmune hemolytical anemia (AIHA). In this study, a murine AIHA model was utilized to investigate the application of cryopreserved fetal liver cells (cFLC), from varying gestation intervals (14 and 19 postcoital days) to correct the functional state of the lymphohemopoietic complex (LHPC). The results demonstrate that cryopreservation had little negative effect on FLC-14 corrective ability from that of nonfrozen FLC-14. Cryopreservation of FLC-19 (later gestation period) resulted in an increase in functional cor-rective potential over that of matched controls. Further, the increase in corrective effect of the cFLC-19 was found to be similar to that of both FLC-14 populations. In summary, these results demonstrate the potential for the use of cryopreserved FLCs as a therapeutic option for the treatment of AIHA.
机译:已经探索了冷冻保存的胎盘复合细胞(FPCP)的治疗潜力,以治疗自身免疫性疾病,包括自身免疫性溶血性贫血(AIHA)。在这项研究中,小鼠AIHA模型被用于研究冷冻保存的胎儿肝细胞(cFLC)在不同的妊娠间隔(性交后14天和19天)中的应用,以纠正淋巴细胞生成复合体(LHPC)的功能状态。结果表明,与未冷冻的FLC-14相比,冷冻保存对FLC-14的校正能力几乎没有负面影响。冷冻保存FLC-19(妊娠后期)导致功能矫正电位比匹配的对照组高。此外,发现cFLC-19的纠正效果增加与两个FLC-14人群的纠正效果相似。总之,这些结果证明了将冷冻保存的FLC用作AIHA的治疗选择的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号